


Magnus Groth

President and CEO





Summary Q1

Solid performance with higher sales and strong cash flow

- All business areas contributing to sales growth
- Higher prices and positive mix, stable volumes
- Strong growth in high-margin categories
- Higher COGS and SG&A
- Strong cash flow and balance sheet





New Share Buyback Program

Allocation of Strong Operating Cash Flow

- Essity B share buyback program of SEK 3bn
- Begins April 24, 2025 and extends until AGM 2026 at the latest
- Safe Harbour compliant
- Ambition to use as a recurring part of Essity's capital allocation





Product launches Q1 2025










Product launches Q1 2025







Product superiority We keep raising the bar









Tariffs






Net sales 2024 per region



Essity's manufacturing footprint



North America

- Professional Hygiene
 - >90% produced domestically in US
 - Imports to Canada from US
- Incontinence Products Health Care and Retail
 - Production both in US and Canada with flows in between
- Medical Solutions
 - Some imports to US from Mexico




TISSUE	PROFESSIONAL	PERSONAL	MEDICAL
CONSUMER//PH	HYGIENE	CARE	
MX, Monterrey MX, Sahagún MX, Uruapan	US, Barton, AL US, Bordentown, NJ US, Harrodsburg, KY US, Middletown, OH US, Menasha, WI US, Neenah, WI	US, Bowling Green CA, Drummondville MX, Ecatepec	US, Manchester MX, Reynosa



Conclusion

- A majority of Essity's products are locally manufactured
- More than 80% of our US sales is produced in the US with material mainly sourced within US
- Imports/exports between US and China are limited
- A majority of the flows between US/Canada/Mexico are exempt or under USMCA agreement
- For parts that are impacted we will minimize the impact by optimizing import and export flows
- Price adjustments and continuous efficiency improvements to further mitigate






Fredrik Rystedt EVP and CFO





Three attractive business areas









Health & Medical


Q1 2025 vs Q1 2024

Organic sales growth +1.7%

- Volume +1.3%
- Price/mix +0.4%
- Incontinence Products Health Care -0.1%
- Medical Solutions +4.2%

Profitability

- EBITA excl. IAC SEK 1,231m, -5%
- EBITA margin excl. IAC 17.7%, -120bps



Consumer Goods


Q1 2025 vs Q1 2024

Organic sales growth +2.9%

- Volume +1.2%
- Price/Mix +1.7%
- Incontinence Products Retail +6.9%
- Feminine Care +5.1
- Baby Care -6.5%
- Consumer Tissue +2.7%

Profitability

- EBITA excl. IAC SEK 2,443m, -4%
- EBITA margin excl. IAC 12.7%, -50bps






Professional Hygiene Q1 2025 vs Q1 2024

Organic sales growth +0.7%

- Volume -3.6%
- Higher prices and positive mix +4.3%


Profitability

- EBITA excl. IAC SEK 1,413m, +6%
- EBITA margin excl. IAC 16.1%, +80bps






Higher sales prices and positive mix





EBITA margin excl. IAC






Strong cash flow generation






Strengthened balance sheet





Magnus Groth


President and CEO





Summary

- A solid Q1 with positive sales growth in all business areas, stable profitability and strong cash flow
- Strong growth platform with leading market positions
- Efficient supply chain with manufacturing close to customers and consumers
- Uncertainty remains regarding global macro economy and consumer sentiment
- We are committed to the ambition of accelerating profitable growth and deliver on strategy and targets





This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncertainties.





essity

Q&A



ee essity